知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

72 条记录 (耗时 0.03 秒)

    Copolymer of (meth)acryloxy-alkyl-siloxysilane and alkyl(meth)acrylates and the use thereof as pressure sensitive adhesives
    1.
    发明授权
    Copolymer of (meth)acryloxy-alkyl-siloxysilane and alkyl(meth)acrylates and the use thereof as pressure sensitive adhesives 失效
    （甲基）丙烯酰氧基 - 烷基 - 硅氧烷硅烷和（甲基）丙烯酸烷基酯的共聚物及其作为压敏粘合剂的用途

    公开(公告)号：US5288827A

    公开(公告)日：1994-02-22

    申请号：US18667

    申请日：1993-02-17

    申请人： Xiaoling Li ,  Bret Berner

    发明人： Xiaoling Li ,  Bret Berner

    IPC分类号： C08F220/18 ,  C08F30/08 ,  C08F220/10 ,  C08F230/08

    CPC分类号： C08F230/08 ,  Y10S526/931

    摘要： A new polymer, the feed monomers and molar percents of which, exclusive of a polymerization initiator and crosslinker, are:A.(I) 42 mole % to 58 mole % of a siloxy silane of formula I,(II) 42 mole % to 58 mole % of an unsubstituted alkyl (meth)acrylate of formula II,(III) 0 to 5 mole % of a Group A monomer, and(IV) 0 to 16 mole % of an additional vinylic copolymerizable monomer;B.(I) 42 mole % to 58 mole % of a siloxy silane of formula I,(II) 21 mole % up to less than 42 mole % of an unsubstituted alkyl (meth)acrylate of formula II,(III) 0 to 5 mole % of a Group A monomer, and(IV) 0 to 29 mole % of an additional vinylic copolymerizable monomer, orC.(I) 16 mole % up to less than 42 mole % of a siloxy silane of formula I,(II) 42 mole % of 58 mole % of an unsubstituted alkyl (meth)acrylate of formula II,(III) 0 to 5 mole % of a Group A monomer, and(IV) 0 to 36 mole % of an additional vinylic copolymerizable monomer,where formula I is ##STR1## where formula II is ##STR2## where Group A is a vinylic acid or a (meth)acrylate as defined herein. Methods of manufacture of the polymer and the use thereof as a pressure adhesive, especially a transdermal and/or transmucosal delivery system pressure sensitive adhesive, are also claimed.

    摘要翻译： 一种新的聚合物，不包括聚合引发剂和交联剂的进料单体和摩尔百分数为：A.（I）42摩尔％至58摩尔％的式I的（甲氧基）硅烷，（II）为42摩尔％ 58摩尔％的式II，（III）的未取代的（甲基）丙烯酸烷基酯，（III）0-5摩尔％的A组单体，和（Ⅳ）0-16摩尔％的另外的乙烯基可共聚单体; B.（I）42摩尔％至58摩尔％的式I，（II）的甲硅烷氧基硅烷，21摩尔％至至少少于42摩尔％的式II，（III）的未取代的（甲基）丙烯酸烷基酯， 5摩尔％的A组单体，和（IV）0-29摩尔％的另外的乙烯基可共聚单体，或C.（I）16摩尔％至多至少于42摩尔％的式I的甲硅烷氧基硅烷，（ II）42摩尔％的58摩尔％的式II，（III）的未取代的（甲基）丙烯酸烷基酯，0-5摩尔％的A组单体，和（Ⅳ）0-36摩尔％的另外的乙烯基可共聚单体 其中式I是（*化学结构*）（I），其中式II是（*化学结构*）（II），其中A组是本文定义的乙烯基酸或（甲基）丙烯酸酯。 还要求保护聚合物的制造方法及其作为压力粘合剂，特别是透皮和/或经粘膜递送系统压敏粘合剂的用途。

    Copolymer of (meth)acryloxy-alkyl-siloxysilane and alkyl(meth)acrylates and the use thereof as pressure sensitive adhesives
    2.
    发明授权
    Copolymer of (meth)acryloxy-alkyl-siloxysilane and alkyl(meth)acrylates and the use thereof as pressure sensitive adhesives 失效
    （甲基）丙烯酰氧基 - 烷基 - 硅氧烷硅烷和（甲基）丙烯酸烷基酯的共聚物及其作为压敏粘合剂的用途

    公开(公告)号：US5376378A

    公开(公告)日：1994-12-27

    申请号：US148040

    申请日：1993-11-04

    申请人： Xiaoling Li ,  Bret Berner

    发明人： Xiaoling Li ,  Bret Berner

    IPC分类号： C08F220/18 ,  C08F30/08 ,  C08F220/10 ,  C08F230/08 ,  A61L15/58

    CPC分类号： C08F230/08 ,  Y10S526/931

    摘要： A new polymer, the feed monomers and molar percents of which, exclusive of a polymerization initiator and crosslinker, are:A. (I) 42 mole % to 58 mole % of a siloxy silane of formula I,(II) 42 mole % to 58 mole % of an unsubstituted alkyl (meth)acrylate of formula II,(III) 0 to 5 mole % of a Group A monomer, and(IV) 0 to 16 mole % of an additional vinylic copolymerizable monomer;B. (I) 42 mole % to 58 mole % of a siloxy silane of formula I,(II) 21 mole % up to less than 42 mole % of an unsubstituted alkyl (meth)acrylate of formula II,(III) 0 to 5 mole % of a Group A monomer, and(IV) 0 to 29 mole % of an additional vinylic copolymerizable monomer; orC. (I) 16 mole % up to less than 42 mole % of a siloxy silane of formula I,(II) 42 mole % to 58 mole % of an unsubstituted alkyl (meth)acrylate of formula II,(III) 0 to 5 mole % of a Group A monomer, and(IV) 0 to 36 mole % of an additional vinylic copolymerizable monomer;where formula I is ##STR1## where formula II is ##STR2## in which R.sub.3 is hydrogen or methyl; and R.sub.4 is methyl or a linear or branched chain C.sub.2-10 alkyl which is unsubstituted;where Group A is (meth)acrylic acid, maleic acid, fumaric acid, itaconic acid, itaconic acid, cinnamic acid, crotonic acid, fumaric acid, maleic acid, 2-(methy)acroyloxyethyl sulfonic acid, 2-(meth)acrylamido-2-methylpropane sulfonic acid, vinyl sulfonic acid, p-styrene sulfonioc acid, allyl sulfonic acid or of formula III.

    摘要翻译： 一种新的聚合物，不包括聚合引发剂和交联剂的进料单体和摩尔百分数为：A.（I）42摩尔％至58摩尔％的式I的（甲氧基）硅烷，（II）为42摩尔％ 58摩尔％的式II，（III）的未取代的（甲基）丙烯酸烷基酯，（III）0-5摩尔％的A组单体，和（Ⅳ）0-16摩尔％的另外的乙烯基可共聚单体; B.（I）42摩尔％至58摩尔％的式I，（II）的甲硅烷氧基硅烷，21摩尔％至至少少于42摩尔％的式II，（III）的未取代的（甲基）丙烯酸烷基酯， 5摩尔％的A组单体，和（IV）0-29摩尔％的另外的乙烯基可共聚单体; 或C（I）16摩尔％至至少42摩尔％的式I的甲硅烷氧基硅烷，（II）42摩尔％至58摩尔％的未取代的式II的（甲基）丙烯酸烷基酯，（III）0 至5摩尔％的A组单体，和（IV）0至36摩尔％的另外的乙烯基可共聚单体; 其中式I是其中式II是和R 4是甲基的式I（I）或未被取代的直链或支链C 2-10烷基; 其中A组为（甲基）丙烯酸，马来酸，富马酸，衣康酸，衣康酸，肉桂酸，巴豆酸，富马酸，马来酸，2-（甲基）丙酰氧基乙基磺酸，2-（甲基）丙烯酰胺基 - 2-甲基丙磺酸，乙烯基磺酸，对苯乙烯磺酸，烯丙基磺酸或式III化合物。

    Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract
    4.
    发明授权
    Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract 有权
    胃酸滞留剂用于将阿坎酸延长释放到上消化道

    公开(公告)号：US09000046B2

    公开(公告)日：2015-04-07

    申请号：US13247956

    申请日：2011-09-28

    申请人： Bret Berner ,  Cuiping Chen

    发明人： Bret Berner ,  Cuiping Chen

    IPC分类号： A61K31/16 ,  A61K9/22 ,  A61K9/26 ,  A61K31/185 ,  A61K9/00 ,  A61K9/20

    CPC分类号： A61K9/0065 ,  A61K9/2027 ,  A61K9/2031 ,  A61K9/2054 ,  A61K31/185 ,  A61K47/10

    摘要： Gastric retentive dosage forms for sustained release of acamprosate are described which may allow once- or twice-daily dosing for both acute and long-term treatment of a disorder including alcohol dependence, tinnitus, sleep apnea, Parkinson's disease, levodopa-induced dyskinesias in Parkinson's disease, Alzheimer's disease, Huntington's disease, Amyotrophic lateral sclerosis, Cortical spreading depression, migraine, schizophrenia, anxiety, tardive dyskinesia, spasticity, multiple sclerosis, various types pain, or binge eating. Methods of treatment using the dosage forms and methods of making the dosage forms are also described.

    摘要翻译： 描述了用于持续释放阿坎酸的胃滞留剂型，其可以允许急性和长期治疗包括酒精依赖性，耳鸣，睡眠呼吸暂停，帕金森病，左旋多巴诱导的帕金森氏症运动障碍的疾病的每日一次或两次 疾病，阿尔茨海默病，亨廷顿舞蹈病，肌萎缩性侧索硬化，皮质扩张抑郁症，偏头痛，精神分裂症，焦虑症，迟发性运动障碍，痉挛性，多发性硬化，各种类型的疼痛或暴饮暴食。 还描述了使用剂型和制备剂型的方法的治疗方法。

    GASTRIC RETENTIVE DOSAGE FORMS FOR EXTENDED RELEASE OF ACAMPROSATE INTO THE UPPER GASTROINTESTINAL TRACT
    5.
    发明申请
    GASTRIC RETENTIVE DOSAGE FORMS FOR EXTENDED RELEASE OF ACAMPROSATE INTO THE UPPER GASTROINTESTINAL TRACT 有权
    胃肠增强剂用于延长胃肠激素释放的胃肠道剂量

    公开(公告)号：US20120077878A1

    公开(公告)日：2012-03-29

    申请号：US13247956

    申请日：2011-09-28

    申请人： Bret Berner ,  Cuiping Chen

    发明人： Bret Berner ,  Cuiping Chen

    IPC分类号： A61K31/185 ,  A61P25/32

    CPC分类号： A61K9/0065 ,  A61K9/2027 ,  A61K9/2031 ,  A61K9/2054 ,  A61K31/185 ,  A61K47/10

    摘要： Gastric retentive dosage forms for sustained release of acamprosate are described which may allow once- or twice-daily dosing for both acute and long-term treatment of a disorder including alcohol dependence, tinnitus, sleep apnea, Parkinson's disease, levodopa-induced dyskinesias in Parkinson's disease, Alzheimer's disease, Huntington's disease, Amyotrophic lateral sclerosis, Cortical spreading depression, migraine, schizophrenia, anxiety, tardive dyskinesia, spasticity, multiple sclerosis, various types pain, or binge eating. Methods of treatment using the dosage forms and methods of making the dosage forms are also described.

    摘要翻译： 描述了用于持续释放阿坎酸的胃滞留剂型，其可以允许急性和长期治疗包括酒精依赖性，耳鸣，睡眠呼吸暂停，帕金森病，左旋多巴诱导的帕金森氏症运动障碍的疾病的每日一次或两次 疾病，阿尔茨海默病，亨廷顿舞蹈病，肌萎缩性侧索硬化，皮质扩张抑郁症，偏头痛，精神分裂症，焦虑症，迟发性运动障碍，痉挛性，多发性硬化，各种类型的疼痛或暴饮暴食。 还描述了使用剂型和制备剂型的方法的治疗方法。

    Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
    8.
    发明授权
    Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms 有权
    片剂形状以增强可膨胀控释口服剂型的胃滞留

    公开(公告)号：US06488962B1

    公开(公告)日：2002-12-03

    申请号：US09598061

    申请日：2000-06-20

    申请人： Bret Berner ,  Jenny Louie-Helm

    发明人： Bret Berner ,  Jenny Louie-Helm

    IPC分类号： A61K914

    CPC分类号： A61K9/0065 ,  A61K9/2031 ,  A61K9/2072

    摘要： The retention of oral drug dosage forms in the stomach is improved by using swellable dosage forms that are shaped in a manner that will prevent them from inadvertently passing through the pylorus as a result of being in a particular orientation. The planar projection of the shape is one that has two orthogonal axes of different lengths, the longer being short enough to permit easy swallowing prior to swelling while the shorter is long enough within one-half hour of swelling to prevent passage through the pylorus.

    摘要翻译： 口服药物剂型在胃中的保留通过使用可膨胀的剂型来改善，其可以以防止它们因特定方向而无意地穿过幽门的方式成型。 形状的平面突起是具有不同长度的两个正交轴的平面突起，其长度足够短以允许在肿胀之前容易吞咽，而较短的时间足以在半小时内膨胀以防止通过幽门。

    Temporally controlled drug delivery systems
    9.
    发明授权
    Temporally controlled drug delivery systems 失效
    临时控制药物输送系统

    公开(公告)号：US06068853A

    公开(公告)日：2000-05-30

    申请号：US542580

    申请日：1995-10-13

    申请人： Steven Andrew Giannos ,  Steven Minh Dinh ,  Bret Berner

    发明人： Steven Andrew Giannos ,  Steven Minh Dinh ,  Bret Berner

    IPC分类号： A61K9/00 ,  A61K9/70

    CPC分类号： A61K9/7084 ,  A61K9/0002

    摘要： A delivery mechanism and device for the passive periodic release of a drug or an active ingredient which avoids the need for external power sources and/or electronic controllers. By taking advantage of oscillating chemical systems, one can change the state, i.e. the pH, of a solution, a drug, enhancer or solubilizer resulting in oscillating the ability of an active ingredient to be delivered transdermally. The pH of a solution can be oscillated over a range of pH values from 2 to 10 by the reduction and oxidation (redox) reactions of salts, such as permanganates, iodates, sulfates, chlorates, or bromates. Upon activation, the delivery system conditions begin to oscillate and with it, the delivery of the active agent oscillates.

    摘要翻译： 用于药物或活性成分的被动定期释放的递送机制和装置，其避免需要外部电源和/或电子控制器。 通过利用振荡化学体系，可以改变溶液，药物，增强剂或增溶剂的状态，即pH，导致活性成分经皮递送的能力的振荡。 通过盐，如高锰酸盐，碘酸盐，硫酸盐，氯酸盐或溴酸盐的还原和氧化（氧化还原）反应，溶液的pH可以在2至10的pH范围内振荡。 在激活时，递送系统条件开始振荡并且随之而起，活性剂的递送振荡。

    Article useful for administration of pharmacologically-active substances transdermally, orally or by means of implant
    10.
    发明授权
    Article useful for administration of pharmacologically-active substances transdermally, orally or by means of implant 失效
    用于透皮，口服或通过植入物施用药理活性物质的物品

    公开(公告)号：US5468501A

    公开(公告)日：1995-11-21

    申请号：US385205

    申请日：1995-02-08

    申请人： Agis Kydonieus ,  Kishore R. Shah ,  Bret Berner

    发明人： Agis Kydonieus ,  Kishore R. Shah ,  Bret Berner

    IPC分类号： A61K9/70 ,  A61K31/21 ,  A61M31/00 ,  A61F13/00

    CPC分类号： A61K9/7084 ,  A61K31/21 ,  A61M31/002

    摘要： A device useful for administration of pharmacologically-active substances transdermally, orally, or by means of subdermal implant includes an impermeable backing layer, a plasticized polyvinyl chloride layer, and an adhesive layer, wherein the plasticized polyvinyl chloride layer includes from about 20 up to about 70% by weight of a polyvinyl chloride resin, from about 20 up to about 70% by weight of a plasticizer, and from about 0.5 up to about 35% by weight of a pharmacologically-active substance such as isosorbide dinitrate, nicotine, clonidine, guanfacine, indomethacin, nitroglycerin, and prostaglandin and optionally excipients.

    摘要翻译： 用于通过皮下，口服或通过皮下植入来施用药理活性物质的装置包括不渗透背衬层，塑化聚氯乙烯层和粘合剂层，其中增塑聚氯乙烯层包括约20至约约 70重量％的聚氯乙烯树脂，约20至约70重量％的增塑剂和约0.5至约35重量％的药理活性物质如硝酸异山梨酯，尼古丁，可乐定， 胍法辛，吲哚美辛，硝酸甘油和前列腺素以及任选的赋形剂。